By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Nanosphere announced after the close of the market on Monday that it intends to offer 13.6 million shares of its common stock in a public offering.

The shares will be priced at $2.20 per share and Nanosphere expects proceeds from the offering to be about $27.9 million. If the underwriters exercise their over-allotment option in full, net proceeds will be about $32.1 million, it added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.